Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC
研究单位：[1]BeiGene[2]Tongji Hospital of Tongji Medical College Huazhong University of Science Technology Wuhan, China, Hubei[3]Hospital of Lithuanian University of Health Sciences Kaunas Clinics branch Oncology Hospital Kaunas, Lithuania[4]Hospital of Lithuanian University of Health Sciences Kaunas Clinics Kaunas, Lithuania[5]National Cancer Institute Vilnius, Lithuania[6]The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou, Zhejiang, China[7]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China[8]The First Affiliated Hospital of Wenzhou Medical University Wenzhou, Zhejiang, China[9]Investigacion Onco Farmaceutica (OncoTech) La Paz, Baja California Sur, Mexico, 23040[10]Health Pharma Professional Research S.A. de C.V. Mexico, Distrito Federal, Mexico, 03810[11]Fundacion Rodolfo Padilla Padilla, A.C. León, Guanajuato, Mexico, 37000[12]Accelerium S de RL de CV Monterrey, Nuevo León, Mexico, 64000[13]Auckland City Hospital Grafton, New Zealand, 1023[14]Waikato Hospital Hamilton, New Zealand[15]Tauranga Hospital Tauranga, New Zealand, 3112[16]SP Zespol Gruzlicy i Chorob Pluc w Olsztynie Olsztyn, Poland, 10-357[17]Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna Łódź, Poland, 90-242[18]SBIH of Arkhangelsk region "Arkhangelsk Clinical Oncological Dispensary" Arkhangel'sk, Russian Federation, 163045[19]Irkutsk Regional Oncology Dispensary Irkutsk, Russian Federation, 664011[20]FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin" Moscow, Russian Federation, 115478
研究目的：
The purpose of this study is to show that BGB-A317 will improve overall survival in participants with Stage IIIB or IV non-small cell lung cancer when compared to docetaxel in second or third-line treatment setting.
